Reports Q1 revenue $8.77B, consensus $8.92B. “Lilly’s first quarter performance reflects solid year-over-year revenue growth with strong sales of Mounjaro and Zepbound,” said David A. Ricks, Lilly’s chair and CEO. “Our progress in addressing some of the world’s most significant health care challenges has resulted in increased demand for our medicines. As we continue to make pipeline investments that position us for future growth, we are rapidly expanding manufacturing capacity to make our incretin medicines available to more patients.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum
- Options Volatility and Implied Earnings Moves This Week, April 29 – May 02, 2024
- Eli Lilly And Company (LLY) Q1 Earnings Cheat Sheet
- LLY vs. JNJ: Which Big Pharma Stock Is Better?
- Eli Lilly (NYSE:LLY) Notches Up on New Manufacturing Plans